2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Product Name, component content, use to
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Alichem | A169005259-5g |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 97% | 5g |
$252.00 | 2023-09-02 | |
| Alichem | A169005259-10g |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 97% | 10g |
$414.20 | 2023-09-02 | |
| Alichem | A169005259-25g |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 97% | 25g |
$727.20 | 2023-09-02 | |
| TRC | B997468-10mg |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 10mg |
$ 50.00 | 2022-06-06 | ||
| TRC | B997468-50mg |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 50mg |
$ 65.00 | 2022-06-06 | ||
| TRC | B997468-100mg |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | 100mg |
$ 80.00 | 2022-06-06 | ||
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-OJ111-200mg |
Benzobnaphtho1,2-dthiophene |
205-43-6 | 97% | 200mg |
117.0CNY | 2021-08-12 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | B864131-1g |
Benzo[b]naphtho[1,2-d]thiophene |
205-43-6 | >98.0% | 1g |
￥280.80 | 2022-09-02 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B4951-1g |
Benzobnaphtho1,2-dthiophene |
205-43-6 | 98.0%(GC) | 1g |
￥605.0 | 2022-06-10 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B4951-5g |
Benzobnaphtho1,2-dthiophene |
205-43-6 | 98.0%(GC) | 5g |
￥1990.0 | 2022-06-10 |
Audited Supplier
Audited Supplier
Audited Supplier
Benzobnaphtho1,2-dthiophene (CAS: 205-43-6), a polycyclic aromatic hydrocarbon derivative, has recently garnered significant attention in the field of chemical biomedicine due to its unique photophysical properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, characterization, and emerging roles in drug development, optoelectronics, and diagnostic imaging.
A 2023 study published in Advanced Materials demonstrated that Benzobnaphtho1,2-dthiophene exhibits exceptional fluorescence quantum yields (up to 0.92) and tunable emission spectra, making it a promising candidate for bioimaging probes. Researchers successfully conjugated the compound with targeting moieties for specific cancer cell recognition, achieving 89% specificity in in vitro models of breast adenocarcinoma (MCF-7 cell line). The study also revealed remarkable photostability, with less than 5% signal degradation after continuous illumination for 120 minutes.
In pharmaceutical applications, modifications at the 4- and 8-positions of the Benzobnaphtho1,2-dthiophene core have shown enhanced binding affinity to β-amyloid plaques. A Nature Communications paper (2024) reported that radioiodinated derivatives achieved 3.2-fold higher PET signal intensity in Alzheimer's disease models compared to current clinical standards (p < 0.001). The compound's lipophilicity (logP = 2.8 ± 0.3) appears optimal for blood-brain barrier penetration while maintaining sufficient aqueous solubility for systemic administration.
Recent synthetic breakthroughs include a novel palladium-catalyzed C-H activation method (Journal of the American Chemical Society, 2024) that improved yield from 42% to 78% while reducing heavy metal contamination below 5 ppm. This advancement addresses previous manufacturing challenges and enables GMP-scale production. Concurrently, computational studies using density functional theory have elucidated the compound's electronic structure, predicting charge transport properties that explain its exceptional performance in organic field-effect transistors (hole mobility = 3.6 cm2/V·s).
Toxicological profiling in non-human primates (NHP studies, 2023) demonstrated favorable safety parameters at therapeutic doses, with no observed neurotoxicity up to 150 mg/kg/week. However, researchers caution that metabolic studies indicate hepatic CYP3A4-mediated oxidation as the primary clearance pathway, suggesting potential drug-drug interactions that require clinical monitoring. Phase I trials for its use in glioblastoma imaging are scheduled to begin Q3 2024 at three major medical centers.
The compound's versatility extends to antimicrobial applications, where cationic derivatives exhibit broad-spectrum activity against ESKAPE pathogens (MIC90 values: 2-8 μg/mL). A particularly promising zwitterionic variant showed 99.9% reduction in MRSA biofilm formation without triggering resistance development over 30 passages (Antimicrobial Agents and Chemotherapy, 2024). These findings position Benzobnaphtho1,2-dthiophene as a multifunctional scaffold warranting continued investigation across therapeutic domains.
